1 / 6

Lung Cancer Diagnostic and Screening Market : Comprehensive Overview

Lung cancer screening is an interaction that is utilized to recognize the presence of lung cancer in a healthy person with a high danger of lung cancer. Lung cancer screening is suggested for old adults who are accustomed to long-term smoking habits and don't convey any signs of lung cancer. <br><br>READ MORE : https://www.tmrresearch.com/lung-cancer-diagnostic-and-screening-market<br><br>

apoorvam
Download Presentation

Lung Cancer Diagnostic and Screening Market : Comprehensive Overview

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. LUNG CANCER DIAGNOSTIC AND SCREENING MARKET Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2021-2031 TMRResearch www.tmrresearch.com

  2. LUNG CANCER DIAGNOSTIC AND SCREENING MARKET 1MARKETOVERVIEW Lung cancer screening is an interaction that is utilized to recognize the presence of lung cancer in a healthy person with a high danger of lung cancer. Lung cancer screening is suggested for old adults who are accustomed to long-term smoking habits and don't convey any signs of lung cancer. TMRResearch www.tmrresearch.com

  3. LUNG CANCER DIAGNOSTIC AND SCREENING MARKET 2NOTABLE PLAYERS Sanofi, Myriad Genetics Inc., Thermo Fischer Scientific, Illumina Inc., NeoGenomics, Janssen Pharmaceuticals Inc., QIAGEN, F.Hoffmann-La Roche Ltd., Danaher, Abbott, Quest Diagnostics Incorporated, NanoString, AstraZeneca TMRResearch www.tmrresearch.com

  4. LUNG CANCER DIAGNOSTIC AND SCREENING MARKET 3DEVELOPMENT The first liquid biopsy companion diagnostic test was approved by the United States FDA for the identification of patients with specific mutation that will help in the growth of the EGFR or epidermal growth factor receptor gene via the next-generation technology or NGS. TMRResearch www.tmrresearch.com

  5. LUNG CANCER DIAGNOSTIC AND SCREENING MARKET 4REGIONAL OUTLOOK Regionwise, the market is dominated by North America on account of the presence of high smoker population and a well-established healthcare center for sufficing to the treatment needs of patients with lung cancer. TMRResearch www.tmrresearch.com

  6. TMRResearch www.tmrresearch.com SampleDiscount Check link indescription

More Related